Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Immuron Limited is a biotechnology business based in the US. Immuron shares (IMRN) are listed on the NASDAQ and all prices are listed in US Dollars.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $3.71 |
|---|---|
| 52-week range | $2.32 - $9.23 |
| 50-day moving average | $3.12 |
| 200-day moving average | $4.30 |
| Wall St. target price | $6.41 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.08 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.71 from 2022-01-25
| 1 week (2022-01-19) | -3.39% |
|---|---|
| 1 month (2021-12-23) | 27.93% |
| 3 months (2021-10-26) | -2.11% |
| 6 months (2021-07-26) | -23.51% |
| 1 year (2021-01-26) | -50.80% |
|---|---|
| 2 years (2020-01-23) | 7.23% |
| 3 years (2019-01-25) | 6.887 |
| 5 years (2017-01-22) | N/A |
| Revenue TTM | $145,776 |
|---|---|
| Gross profit TTM | $-665,060 |
| Return on assets TTM | -29.92% |
| Return on equity TTM | -53.17% |
| Profit margin | 0% |
| Book value | $4.56 |
| Market capitalisation | $21.1 million |
TTM: trailing 12 months
We're not expecting Immuron to pay a dividend over the next 12 months.
Over the last 12 months, Immuron's shares have ranged in value from as little as $2.32 up to $9.23. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Immuron's is 1.8724. This would suggest that Immuron's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia. .
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.